The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis.
Chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis (CF) are characterized by airway obstruction and an inflammatory process. Reaching early diagnosis and discrimination of subtypes of these respiratory diseases are quite a challenging task than other chronic illnesses. Metabolomics is the study of metabolic pathways and the measurement of unique biochemical molecules generated in a living system. In the last decade, metabolomics has already proved to be useful for the characterization of several pathological conditions and offers promises as a clinical tool. In this article, we review the current state of the metabolomics of COPD, asthma and CF with a focus on the different methods and instrumentation being used for the discovery of biomarkers in research and translation into clinic as diagnostic aids for the choice of patient-specific therapies.
Faculty of Paramedical Sciences, Proteomics Research Center, Shahid Beheshti University of Medical Sciences , Tehran , Iran .
B Fatemeh
BF
Nobakht M Gh
Rasoul
R
Aliannejad
Mostafa
M
Rezaei-Tavirani
Salman
S
Taheri
Afsaneh Arefi
AA
Oskouie
D000818:Animals; D001249:Asthma / Q000175:diagnosis / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism; D003550:Cystic Fibrosis / Q000175:diagnosis / Q000378:metabolism*; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D055432:Metabolomics; D029424:Pulmonary Disease, Chronic Obstructive / Q000175:diagnosis / Q000378:metabolism*
D015415:Biomarkers
Asthma; NMR spectroscopy; chronic obstructive pulmonary disease; cystic fibrosis; mass spectrometry; metabolomics